Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2024-02-20 Regulatory Filings
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Form 8-K - CEO Letter
Regulatory Filings Classification · 93% confidence The document explicitly states it is a "FORM 8-K" filed pursuant to the Securities Exchange Act of 1934, dated February 20, 2024. Item 8.01 mentions that the registrant issued a press release containing a letter to shareholders, which is attached as Exhibit 99.1. The main body of the text provided is this 'Letter to Shareholders' from the CEO, which discusses business updates, clinical trial progress (Phase 3 oral insulin), joint ventures (HTIT), financing (Scilex Note), and acquisitions (PeriTech). A Form 8-K is used to report major, unscheduled material events. While the content resembles an Investor Presentation (IP) or Management Discussion (MDA) due to its detailed operational updates, the *filing type* itself is the Form 8-K. Since Form 8-K is not an explicit category, we must determine the best fit based on the content's primary purpose within the provided list. The content is a comprehensive update on operations, strategy, and financial events, which aligns closely with the function of an Earnings Release (ER) or Interim Report (IR) in terms of content scope, but it is specifically a report on 'Other Events' (Item 8.01) and includes a shareholder letter. Given the comprehensive nature of the updates (clinical, JV, financing, acquisition) presented in a letter format, it functions as a detailed management update accompanying the required regulatory filing. However, none of the codes perfectly match 'Form 8-K'. The closest functional equivalents for detailed operational/financial updates are ER or IR. Since this is not a standard quarterly/annual financial report, and it's an unscheduled event report, the most appropriate classification among the choices for a detailed, non-standard operational/strategic update accompanying a regulatory filing is often the Investor Presentation (IP) if it were a presentation, or the Management Reports (MDA) for the detailed explanation. Since the core document is the Form 8-K reporting on these events, and the content is a detailed CEO letter explaining business progress, 'MDA' (Management Reports) is the best fit for the *content* being conveyed, as it is a management explanation of business trends and outlook, even though the wrapper is an 8-K. If 8-K were an option, it would be chosen. Lacking 8-K, MDA captures the essence of the detailed narrative update.
2024-02-20 English
Form 8-K - CEO Letter
Report Publication Announcement Classification · 98% confidence The document is a filing notification from ORAMED PHARMACEUTICALS INC, referencing the Israel Securities Authority and the Tel Aviv Stock Exchange. It explicitly states: "Attached hereto is a report on *Form 8-K - CEO Letter*" and provides a PDF filename. Since the document itself is a notification announcing the availability of an attached report (a CEO Letter filed on Form 8-K, which is a general SEC filing), and given its very short length (1890 chars), it fits the criteria for a Report Publication Announcement (RPA) under the 'MENU VS MEAL' rule. It is announcing the publication of a specific report rather than being the report itself. If RPA were not an option, RNS would be a secondary choice, but RPA is more specific for announcing the release of a document.
2024-02-20 English
CURRENT REPORT
Regulatory Filings
2024-02-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Aghion Daniel
Director's Dealing Classification · 98% confidence The document is explicitly titled "FORM 4" and contains the header "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934". Form 4 filings are mandatory SEC disclosures detailing insider transactions (changes in beneficial ownership by directors, officers, or 10% owners). This specific type of filing is not explicitly listed in the provided definitions (AGM-R, 10-K, AR, etc.). However, the closest functional category that covers insider trading reports, which are regulatory filings concerning executive actions, is 'Director's Dealing' (DIRS), as Form 4 is the primary mechanism for reporting such dealings. While DIRS is defined as 'Report of personal share transactions by company directors and executives (insider trades)', Form 4 is the official SEC form for this. Given the options, DIRS is the most appropriate classification for an insider transaction report like Form 4. If DIRS were not available, RNS (Regulatory Filings) would be the fallback, but DIRS is a better fit for the content type.
2024-01-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Aghion Daniel
Report Publication Announcement Classification · 95% confidence The document is a filing from ORAMED PHARMACEUTICALS INC, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The key content states: "Attached hereto is a report on *Form 4 - Daniel Aghion*" followed by a filename. Form 4 filings in the US context (implied by the address and reference to U.S. Securities Laws) relate to insider transactions (directors' or officers' changes in beneficial ownership). This directly corresponds to the definition of Director's Dealing (DIRS). However, the document itself is very short (1882 chars) and explicitly states that the actual report (Form 4) is 'Attached hereto'. According to Rule 2, when a document announces the attachment or publication of another report, it should be classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Since 'Director's Dealing' (DIRS) is a specific category for the content of Form 4, and this document is merely the cover/announcement wrapper, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule, as it is announcing the publication of the actual report. Reviewing the definitions: DIRS is for the report of personal share transactions. RPA is for the announcement regarding the timing, release, or publication of company reports. Since this is an announcement wrapper for a Form 4 filing, RPA is chosen over DIRS based on the document structure and length.
2024-01-30 English
FORM 4 SUBMISSION
Director's Dealing
2024-01-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.